Filana Therapeutics 3Q 2026: EPS ($0.22) — 10-Q Summary

Filana Therapeutics reported a narrower quarterly net loss year over year, as lower research and development and general and administrative expenses more than offset reduced interest income. The company has not generated product sales revenue.Financial Highlights² Reported as “Net loss”. ³ Reported…